Literature DB >> 27239744

Internal consistency and construct validity of the Quality of Life in Alzheimer's Disease (QoL-AD) proxy – a secondary data analysis

Jonas Hylla1, Christian G G Schwab2,3, Michael Isfort1,4, Margareta Halek2,3, Martin N Dichter2,3.   

Abstract

Background: The maintenance and promotion of Quality of Life (QoL) of people with dementia is a major outcome in intervention studies and health care. The Quality of Life Alzheimer's Disease (QoL-AD) is an internationally recommended QoL measurement also available in German language. Until now, only a few results on the psychometric properties of the German QoL-AD were available. Objective: Evaluation of internal consistency and construct validity of the QoL-AD proxy. Method: A principal component analysis (secondary data analysis) of the 13 QoL-AD items was carried out based on the total sample of 234 people with dementia from nine nursing homes in Germany. Subsequently, the internal consistency of the identified factors was examined using Cronbach's alpha.
Results: Two factors physical and mental health and social network were determined. Both factors explain 53 % of the total variance. The stability of both factors was validated in two sensitivity analyses. The internal consistency is good for both factors with a Cronbach's alpha of 0.88 (physical and mental health) and 0.75 (social network).
Conclusion: The QoL-AD proxy allows the assessment of two relevant health-related QoL domains of people with dementia. However, in future studies especially the inter-rater reliability of the QoL-AD proxy has to be examined.

Entities:  

Keywords:  Demenz; Konstruktvalidität; construct validity; dementia; factorial validity; faktorielle Validität; gesundheitsbezogene Lebensqualität; health related quality of life; internal consistency; interne Konsistenz; nursing home; stationäre Altenpflegeeinrichtung

Mesh:

Year:  2016        PMID: 27239744     DOI: 10.1024/1012-5302/a000494

Source DB:  PubMed          Journal:  Pflege        ISSN: 1012-5302            Impact factor:   0.655


  5 in total

1.  Item distribution and inter-rater reliability of the German version of the quality of life in Alzheimer's disease scale (QoL-AD) proxy for people with dementia living in nursing homes.

Authors:  Martin Nikolaus Dichter; Eva-Maria Wolschon; Christian G G Schwab; Gabriele Meyer; Sascha Köpke
Journal:  BMC Geriatr       Date:  2018-06-19       Impact factor: 3.921

2.  Quality of life in persons with dementia using regional dementia care network services in Germany: a one-year follow-up study.

Authors:  Johannes Gräske; Annika Schmidt; Sylvia Schmidt; Franziska Laporte Uribe; Jochen René Thyrian; Bernhard Michalowsky; Susanne Schäfer-Walkmann; Karin Wolf-Ostermann
Journal:  Health Qual Life Outcomes       Date:  2018-09-14       Impact factor: 3.186

3.  Multifactorial intervention for hip and pelvic fracture patients with mild to moderate cognitive impairment: study protocol of a dual-centre randomised controlled trial (OF-CARE).

Authors:  Anja Dautel; Tobias Eckert; Michaela Gross; Klaus Hauer; Martina Schäufele; André Lacroix; Ingrid Hendlmeier; Bastian Abel; Rebekka Pomiersky; Julia Gugenhan; Gisela Büchele; Katrin C Reber; Clemens Becker; Klaus Pfeiffer
Journal:  BMC Geriatr       Date:  2019-04-30       Impact factor: 3.921

4.  Comparing the psychometric properties of EQ-5D-3L and EQ-5D-5L proxy ratings by informal caregivers and a health professional for people with dementia.

Authors:  Bernhard Michalowsky; Wolfgang Hoffmann; Wiebke Mohr; Anika Rädke; Feng Xie
Journal:  Health Qual Life Outcomes       Date:  2022-10-05       Impact factor: 3.077

5.  Effects of strategies to improve general practitioner-nurse collaboration and communication in regard to hospital admissions of nursing home residents (interprof ACT): study protocol for a cluster randomised controlled trial.

Authors:  Christiane Müller; Berit Hesjedal-Streller; Nina Fleischmann; Britta Tetzlaff; Tina Mallon; Martin Scherer; Sascha Köpke; Katrin Balzer; Linda Gärtner; Indre Maurer; Tim Friede; Hans-Helmut König; Eva Hummers
Journal:  Trials       Date:  2020-11-05       Impact factor: 2.279

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.